scholarly journals Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma

2021 ◽  
Vol 17 (2) ◽  
pp. 64-71
Author(s):  
Samer A. Al-Hadidi ◽  
Hun Ju Lee
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
High Dose ◽  
Cell Transplant ◽  
Classic Hodgkin Lymphoma

The checkpoint inhibitors nivolumab and pembrolizumab are principal treatment options for relapsed or refractory classic Hodgkin lymphoma. In patients who decline autologous stem-cell transplantation or who are unsuited for high-dose chemotherapy and subsequent autologous stem-cell transplantation because of comorbidities, the use of checkpoint inhibitors may improve overall survival and have a manageable side effect profile. This clinical review provides an evidence-based summary to guide practicing oncologists in the use of checkpoint inhibitors in relapsed or refractory classic Hodgkin lymphoma and includes checkpoint inhibitor efficacy and adverse effect profiles. We highlight the use of checkpoint inhibitors in the management of relapsed or refractory classic Hodgkin lymphoma in patients who are ineligible for an autologous stem-cell transplant with the goal of improving disease control while limiting adverse events.

scholarly journals Update on Salvage Options in Relapsed/Refractory Hodgkin Lymphoma after Autotransplant

ISRN Oncology ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Nida Iqbal ◽  
Lalit Kumar ◽  
Naveed Iqbal
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Clinical Success ◽  
Treatment Plan ◽  
Treatment Options ◽  
High Dose ◽  
Cell Transplant

Despite a high clinical success, relapse in Hodgkin lymphoma occurs in 10–30% of cases and 5–10% patients are nonresponsive to initial chemotherapy. The standard management of these patients includes high-dose chemotherapy followed by autologous stem cell transplant. However, 50% of patients ultimately relapse after autotransplant which poses a big challenge. Allogeneic stem cell transplantation offers the only chance of cure in these patients. For patients who are not candidates for allogeneic stem cell transplantation, achieving cure with other possible options is highly unlikely, and thus the treatment plan becomes noncurative. Various novel agents have shown promising results but the duration of response is short lived. A standard approach to deliver the most effective treatment for these patients is still lacking. This review focuses on the treatment options currently available for relapsed and refractory disease after autotransplant.

MODERN THERAPY FOR RELAPSES AND RESISTANT FORMS OF HODGKIN''S LYMPHOMA

2018 ◽  
Vol 64 (3) ◽  
pp. 419-428 ◽  
Author(s):  
Sergey Alekseev ◽  
Yevgeniya Kharchenko ◽  
Svetlana Kuleva ◽  
Tatyana Semiglazova
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Checkpoint Inhibitors ◽  
Single Agent ◽  
Young Patients ◽  
High Risk Group ◽  
High Dose ◽  
Cell Transplant

Despite the success of standard front-line chemotherapy for classical Hodgkin lymphoma in part of these patients relapse or resistance are developed. During last years standard therapeutic approach for relapse or refractory disease is still «salvage» following high-dose chemotherapy with autologous stem cell transplantation. Brentuximab vedotin made great revolution in Hodgkin’s lymphoma treatment demonstrated high efficacy not only in relapse treatment but also as consolidation after autologous stem cell transplantation in high-risk group of patients. In the era of new agents for patents with relapses following autologous stem cell transplant there are multiple treatment options including single-agent and polychemotherapy, combination chemotherapy strategies, the immunoconjugate brentuximab, checkpoint inhibitors nivolumab and pembrolizumab. Allogeneic stem cell transplantation could be considered in young patients with chemosensitive tumor in the presence of a bone marrow donor. Therapeutic choice should be always based on age, comorbidities, previous treatment, patient’s preferences and drug availability.

scholarly journals Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Blood ◽  
2010 ◽  
Vol 116 (23) ◽  
pp. 4934-4937 ◽  
Author(s):  
Alison J. Moskowitz ◽  
Joachim Yahalom ◽  
Tarun Kewalramani ◽  
Jocelyn C. Maragulia ◽  
Jill M. Vanak ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Hodgkin Lymphoma ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Functional Imaging ◽  
Cancer Center ◽  
High Dose ◽  
Positron Emission ◽  
Refractory Hodgkin Lymphoma

Abstract To identify prognostic factors for patients transplanted for relapsed or refractory Hodgkin lymphoma we carried out a combined analysis of patients followed prospectively on 3 consecutive protocols at Memorial Sloan-Kettering Cancer Center. One hundred fifty-three patients with chemosensitive disease after ICE (ifosfamide, carboplatin, and etoposide)–based salvage therapy (ST) proceeded to high-dose chemoradiotherapy followed by autologous stem cell transplantation (ASCT). Patients were evaluated with computed tomography and functional imaging (gallium or fluorodeoxyglucose-positron emission tomography) prior to ST and again before ASCT. Functional imaging status before ASCT was the only factor significant for event-free survival (EFS) and overall survival by multivariate analysis and clearly identifies poor risk patients (5-year EFS 31% and 75% for FI-positive and negative patients respectively). Administration of involved-field radiotherapy with ASCT was marginally significant for EFS (P = .055). Studies evaluating novel STs, conditioning regimens, post-ASCT maintenance, or allogeneic stem cell transplantation are warranted for patients who fail to normalize pre-ASCT functional imaging.

Sign in / Sign up

Export Citation Format

Share Document